nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—CYP2C8—Mometasone—atopic dermatitis	0.0538	0.0958	CbGbCtD
Ponatinib—CYP3A5—Tacrolimus—atopic dermatitis	0.0439	0.0782	CbGbCtD
Ponatinib—ABCB11—Dexamethasone—atopic dermatitis	0.0422	0.0751	CbGbCtD
Ponatinib—ABCG2—Hydrocortisone—atopic dermatitis	0.0322	0.0574	CbGbCtD
Ponatinib—CYP2C8—Loratadine—atopic dermatitis	0.0309	0.055	CbGbCtD
Ponatinib—CYP3A4—Pimecrolimus—atopic dermatitis	0.0288	0.0513	CbGbCtD
Ponatinib—ABCB1—Tacrolimus—atopic dermatitis	0.0286	0.0509	CbGbCtD
Ponatinib—ABCB1—Loratadine—atopic dermatitis	0.0209	0.0372	CbGbCtD
Ponatinib—ABCG2—Dexamethasone—atopic dermatitis	0.0201	0.0357	CbGbCtD
Ponatinib—CYP2D6—Loratadine—atopic dermatitis	0.0197	0.0351	CbGbCtD
Ponatinib—CYP2D6—Diphenhydramine—atopic dermatitis	0.0197	0.0351	CbGbCtD
Ponatinib—ABCB1—Methylprednisolone—atopic dermatitis	0.0191	0.0341	CbGbCtD
Ponatinib—CYP3A5—Hydrocortisone—atopic dermatitis	0.0179	0.0318	CbGbCtD
Ponatinib—CYP2C8—Hydrocortisone—atopic dermatitis	0.0172	0.0306	CbGbCtD
Ponatinib—CYP3A4—Tacrolimus—atopic dermatitis	0.0171	0.0305	CbGbCtD
Ponatinib—CYP3A4—Loratadine—atopic dermatitis	0.0125	0.0223	CbGbCtD
Ponatinib—ABCB1—Betamethasone—atopic dermatitis	0.0124	0.0221	CbGbCtD
Ponatinib—ABCB1—Prednisolone—atopic dermatitis	0.0123	0.0218	CbGbCtD
Ponatinib—ABCB1—Hydrocortisone—atopic dermatitis	0.0116	0.0207	CbGbCtD
Ponatinib—ABCB1—Prednisone—atopic dermatitis	0.0116	0.0206	CbGbCtD
Ponatinib—CYP3A4—Methylprednisolone—atopic dermatitis	0.0115	0.0204	CbGbCtD
Ponatinib—CYP3A5—Dexamethasone—atopic dermatitis	0.0111	0.0198	CbGbCtD
Ponatinib—CYP2C8—Dexamethasone—atopic dermatitis	0.0107	0.019	CbGbCtD
Ponatinib—FGFR3—skin epidermis—atopic dermatitis	0.00934	0.167	CbGeAlD
Ponatinib—CYP3A4—Triamcinolone—atopic dermatitis	0.00868	0.0155	CbGbCtD
Ponatinib—CYP3A4—Betamethasone—atopic dermatitis	0.00745	0.0133	CbGbCtD
Ponatinib—CYP3A4—Prednisolone—atopic dermatitis	0.00735	0.0131	CbGbCtD
Ponatinib—ABCB1—Dexamethasone—atopic dermatitis	0.00723	0.0129	CbGbCtD
Ponatinib—CYP3A4—Hydrocortisone—atopic dermatitis	0.00697	0.0124	CbGbCtD
Ponatinib—CYP3A4—Prednisone—atopic dermatitis	0.00694	0.0124	CbGbCtD
Ponatinib—CYP2D6—Dexamethasone—atopic dermatitis	0.00681	0.0121	CbGbCtD
Ponatinib—Nilotinib—MAPK8—atopic dermatitis	0.00643	1	CrCbGaD
Ponatinib—FGFR2—skin epidermis—atopic dermatitis	0.00612	0.109	CbGeAlD
Ponatinib—CYP3A4—Dexamethasone—atopic dermatitis	0.00433	0.00772	CbGbCtD
Ponatinib—KIT—skin epidermis—atopic dermatitis	0.00425	0.0757	CbGeAlD
Ponatinib—RET—neck—atopic dermatitis	0.00308	0.0549	CbGeAlD
Ponatinib—FGFR2—neck—atopic dermatitis	0.00293	0.0522	CbGeAlD
Ponatinib—FGFR3—skin of body—atopic dermatitis	0.00289	0.0516	CbGeAlD
Ponatinib—FGFR4—head—atopic dermatitis	0.00277	0.0494	CbGeAlD
Ponatinib—KDR—neck—atopic dermatitis	0.00229	0.0409	CbGeAlD
Ponatinib—KIT—neck—atopic dermatitis	0.00203	0.0363	CbGeAlD
Ponatinib—LYN—head—atopic dermatitis	0.0019	0.0339	CbGeAlD
Ponatinib—FGFR2—skin of body—atopic dermatitis	0.00189	0.0338	CbGeAlD
Ponatinib—FGFR3—head—atopic dermatitis	0.00189	0.0337	CbGeAlD
Ponatinib—BCR—head—atopic dermatitis	0.00163	0.0291	CbGeAlD
Ponatinib—SRC—skin of body—atopic dermatitis	0.00161	0.0288	CbGeAlD
Ponatinib—KIT—skin of body—atopic dermatitis	0.00132	0.0235	CbGeAlD
Ponatinib—RET—head—atopic dermatitis	0.0013	0.0232	CbGeAlD
Ponatinib—FGFR2—head—atopic dermatitis	0.00124	0.022	CbGeAlD
Ponatinib—TEK—head—atopic dermatitis	0.00119	0.0211	CbGeAlD
Ponatinib—ABL1—skin of body—atopic dermatitis	0.00115	0.0204	CbGeAlD
Ponatinib—PDGFRA—head—atopic dermatitis	0.00107	0.0191	CbGeAlD
Ponatinib—SRC—head—atopic dermatitis	0.00105	0.0188	CbGeAlD
Ponatinib—KDR—head—atopic dermatitis	0.000969	0.0173	CbGeAlD
Ponatinib—KIT—head—atopic dermatitis	0.000859	0.0153	CbGeAlD
Ponatinib—ABL1—head—atopic dermatitis	0.000747	0.0133	CbGeAlD
Ponatinib—CYP2D6—head—atopic dermatitis	0.000323	0.00576	CbGeAlD
Ponatinib—ABCB1—head—atopic dermatitis	0.000232	0.00414	CbGeAlD
Ponatinib—Acute coronary syndrome—Dexamethasone—atopic dermatitis	0.00017	0.000774	CcSEcCtD
Ponatinib—Abdominal distension—Prednisone—atopic dermatitis	0.000169	0.000772	CcSEcCtD
Ponatinib—Eye disorder—Hydrocortisone—atopic dermatitis	0.000169	0.000771	CcSEcCtD
Ponatinib—Myocardial infarction—Betamethasone—atopic dermatitis	0.000169	0.00077	CcSEcCtD
Ponatinib—Neuropathy peripheral—Betamethasone—atopic dermatitis	0.000169	0.00077	CcSEcCtD
Ponatinib—Neuropathy peripheral—Dexamethasone—atopic dermatitis	0.000169	0.00077	CcSEcCtD
Ponatinib—Myocardial infarction—Dexamethasone—atopic dermatitis	0.000169	0.00077	CcSEcCtD
Ponatinib—Gastrointestinal pain—Tacrolimus—atopic dermatitis	0.000168	0.000769	CcSEcCtD
Ponatinib—Connective tissue disorder—Methylprednisolone—atopic dermatitis	0.000167	0.000762	CcSEcCtD
Ponatinib—Arrhythmia—Prednisolone—atopic dermatitis	0.000165	0.000755	CcSEcCtD
Ponatinib—Pancreatitis—Prednisone—atopic dermatitis	0.000165	0.000752	CcSEcCtD
Ponatinib—Vomiting—Mometasone—atopic dermatitis	0.000164	0.000751	CcSEcCtD
Ponatinib—Visual impairment—Methylprednisolone—atopic dermatitis	0.000164	0.000747	CcSEcCtD
Ponatinib—Rash—Mometasone—atopic dermatitis	0.000163	0.000745	CcSEcCtD
Ponatinib—Dermatitis—Mometasone—atopic dermatitis	0.000163	0.000744	CcSEcCtD
Ponatinib—Abdominal pain—Tacrolimus—atopic dermatitis	0.000163	0.000743	CcSEcCtD
Ponatinib—Body temperature increased—Tacrolimus—atopic dermatitis	0.000163	0.000743	CcSEcCtD
Ponatinib—Headache—Mometasone—atopic dermatitis	0.000162	0.00074	CcSEcCtD
Ponatinib—Arrhythmia—Hydrocortisone—atopic dermatitis	0.000161	0.000737	CcSEcCtD
Ponatinib—Erythema—Prednisolone—atopic dermatitis	0.000161	0.000736	CcSEcCtD
Ponatinib—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.000161	0.000735	CcSEcCtD
Ponatinib—Eye disorder—Methylprednisolone—atopic dermatitis	0.000159	0.000725	CcSEcCtD
Ponatinib—Mental disorder—Hydrocortisone—atopic dermatitis	0.000158	0.000723	CcSEcCtD
Ponatinib—Cardiac disorder—Methylprednisolone—atopic dermatitis	0.000158	0.00072	CcSEcCtD
Ponatinib—Erythema—Hydrocortisone—atopic dermatitis	0.000157	0.000718	CcSEcCtD
Ponatinib—Malnutrition—Hydrocortisone—atopic dermatitis	0.000157	0.000718	CcSEcCtD
Ponatinib—Neutropenia—Prednisone—atopic dermatitis	0.000157	0.000717	CcSEcCtD
Ponatinib—Haemoglobin—Dexamethasone—atopic dermatitis	0.000155	0.000709	CcSEcCtD
Ponatinib—Haemoglobin—Betamethasone—atopic dermatitis	0.000155	0.000709	CcSEcCtD
Ponatinib—Erectile dysfunction—Prednisone—atopic dermatitis	0.000155	0.000707	CcSEcCtD
Ponatinib—Haemorrhage—Dexamethasone—atopic dermatitis	0.000154	0.000705	CcSEcCtD
Ponatinib—Haemorrhage—Betamethasone—atopic dermatitis	0.000154	0.000705	CcSEcCtD
Ponatinib—Angiopathy—Methylprednisolone—atopic dermatitis	0.000154	0.000704	CcSEcCtD
Ponatinib—Nausea—Mometasone—atopic dermatitis	0.000154	0.000702	CcSEcCtD
Ponatinib—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.000153	0.000699	CcSEcCtD
Ponatinib—Arrhythmia—Triamcinolone—atopic dermatitis	0.000152	0.000694	CcSEcCtD
Ponatinib—Weight decreased—Prednisone—atopic dermatitis	0.000152	0.000694	CcSEcCtD
Ponatinib—Vision blurred—Prednisolone—atopic dermatitis	0.000152	0.000693	CcSEcCtD
Ponatinib—Arrhythmia—Methylprednisolone—atopic dermatitis	0.000152	0.000693	CcSEcCtD
Ponatinib—Hyperglycaemia—Prednisone—atopic dermatitis	0.000152	0.000692	CcSEcCtD
Ponatinib—Visual impairment—Dexamethasone—atopic dermatitis	0.000149	0.00068	CcSEcCtD
Ponatinib—Visual impairment—Betamethasone—atopic dermatitis	0.000149	0.00068	CcSEcCtD
Ponatinib—Mental disorder—Methylprednisolone—atopic dermatitis	0.000149	0.000679	CcSEcCtD
Ponatinib—Erythema—Triamcinolone—atopic dermatitis	0.000148	0.000677	CcSEcCtD
Ponatinib—Erythema—Methylprednisolone—atopic dermatitis	0.000148	0.000675	CcSEcCtD
Ponatinib—Malnutrition—Methylprednisolone—atopic dermatitis	0.000148	0.000675	CcSEcCtD
Ponatinib—Asthenia—Tacrolimus—atopic dermatitis	0.000148	0.000674	CcSEcCtD
Ponatinib—Acute coronary syndrome—Prednisone—atopic dermatitis	0.000148	0.000674	CcSEcCtD
Ponatinib—Myocardial infarction—Prednisone—atopic dermatitis	0.000147	0.000671	CcSEcCtD
Ponatinib—Neuropathy peripheral—Prednisone—atopic dermatitis	0.000147	0.000671	CcSEcCtD
Ponatinib—Pruritus—Tacrolimus—atopic dermatitis	0.000146	0.000665	CcSEcCtD
Ponatinib—Eye disorder—Betamethasone—atopic dermatitis	0.000144	0.000659	CcSEcCtD
Ponatinib—Eye disorder—Dexamethasone—atopic dermatitis	0.000144	0.000659	CcSEcCtD
Ponatinib—Back pain—Triamcinolone—atopic dermatitis	0.000143	0.000654	CcSEcCtD
Ponatinib—Diarrhoea—Tacrolimus—atopic dermatitis	0.000141	0.000643	CcSEcCtD
Ponatinib—Angiopathy—Dexamethasone—atopic dermatitis	0.00014	0.00064	CcSEcCtD
Ponatinib—Angiopathy—Betamethasone—atopic dermatitis	0.00014	0.00064	CcSEcCtD
Ponatinib—Hypertension—Prednisolone—atopic dermatitis	0.000139	0.000635	CcSEcCtD
Ponatinib—Arrhythmia—Dexamethasone—atopic dermatitis	0.000138	0.00063	CcSEcCtD
Ponatinib—Arrhythmia—Betamethasone—atopic dermatitis	0.000138	0.00063	CcSEcCtD
Ponatinib—Alopecia—Betamethasone—atopic dermatitis	0.000136	0.000623	CcSEcCtD
Ponatinib—Alopecia—Dexamethasone—atopic dermatitis	0.000136	0.000623	CcSEcCtD
Ponatinib—Dizziness—Tacrolimus—atopic dermatitis	0.000136	0.000622	CcSEcCtD
Ponatinib—Hypertension—Hydrocortisone—atopic dermatitis	0.000136	0.00062	CcSEcCtD
Ponatinib—Haemoglobin—Prednisone—atopic dermatitis	0.000135	0.000617	CcSEcCtD
Ponatinib—Haemorrhage—Prednisone—atopic dermatitis	0.000134	0.000614	CcSEcCtD
Ponatinib—Erythema—Dexamethasone—atopic dermatitis	0.000134	0.000614	CcSEcCtD
Ponatinib—Erythema—Betamethasone—atopic dermatitis	0.000134	0.000614	CcSEcCtD
Ponatinib—Myalgia—Hydrocortisone—atopic dermatitis	0.000134	0.000612	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000133	0.000607	CcSEcCtD
Ponatinib—Connective tissue disorder—Prednisone—atopic dermatitis	0.000132	0.000603	CcSEcCtD
Ponatinib—Oedema—Prednisolone—atopic dermatitis	0.000131	0.0006	CcSEcCtD
Ponatinib—Vomiting—Tacrolimus—atopic dermatitis	0.000131	0.000598	CcSEcCtD
Ponatinib—Rash—Tacrolimus—atopic dermatitis	0.00013	0.000593	CcSEcCtD
Ponatinib—Dermatitis—Tacrolimus—atopic dermatitis	0.00013	0.000592	CcSEcCtD
Ponatinib—Cough—Triamcinolone—atopic dermatitis	0.000129	0.00059	CcSEcCtD
Ponatinib—Headache—Tacrolimus—atopic dermatitis	0.000129	0.000589	CcSEcCtD
Ponatinib—Oedema—Hydrocortisone—atopic dermatitis	0.000128	0.000586	CcSEcCtD
Ponatinib—Hypertension—Triamcinolone—atopic dermatitis	0.000128	0.000584	CcSEcCtD
Ponatinib—Hypertension—Methylprednisolone—atopic dermatitis	0.000128	0.000583	CcSEcCtD
Ponatinib—Infection—Hydrocortisone—atopic dermatitis	0.000128	0.000583	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisolone—atopic dermatitis	0.000127	0.00058	CcSEcCtD
Ponatinib—Myalgia—Triamcinolone—atopic dermatitis	0.000126	0.000576	CcSEcCtD
Ponatinib—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000126	0.000575	CcSEcCtD
Ponatinib—Myalgia—Methylprednisolone—atopic dermatitis	0.000126	0.000575	CcSEcCtD
Ponatinib—Arthralgia—Methylprednisolone—atopic dermatitis	0.000126	0.000575	CcSEcCtD
Ponatinib—Eye disorder—Prednisone—atopic dermatitis	0.000126	0.000574	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000125	0.000571	CcSEcCtD
Ponatinib—Flushing—Prednisone—atopic dermatitis	0.000125	0.00057	CcSEcCtD
Ponatinib—Skin disorder—Hydrocortisone—atopic dermatitis	0.000125	0.00057	CcSEcCtD
Ponatinib—Hyperhidrosis—Hydrocortisone—atopic dermatitis	0.000124	0.000567	CcSEcCtD
Ponatinib—Dry mouth—Triamcinolone—atopic dermatitis	0.000123	0.000563	CcSEcCtD
Ponatinib—Nausea—Tacrolimus—atopic dermatitis	0.000122	0.000558	CcSEcCtD
Ponatinib—Angiopathy—Prednisone—atopic dermatitis	0.000122	0.000557	CcSEcCtD
Ponatinib—Oedema—Triamcinolone—atopic dermatitis	0.000121	0.000552	CcSEcCtD
Ponatinib—Arrhythmia—Prednisone—atopic dermatitis	0.00012	0.000549	CcSEcCtD
Ponatinib—Infection—Triamcinolone—atopic dermatitis	0.00012	0.000549	CcSEcCtD
Ponatinib—Infection—Methylprednisolone—atopic dermatitis	0.00012	0.000547	CcSEcCtD
Ponatinib—Insomnia—Prednisolone—atopic dermatitis	0.000119	0.000543	CcSEcCtD
Ponatinib—Alopecia—Prednisone—atopic dermatitis	0.000119	0.000543	CcSEcCtD
Ponatinib—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000118	0.00054	CcSEcCtD
Ponatinib—Paraesthesia—Prednisolone—atopic dermatitis	0.000118	0.000539	CcSEcCtD
Ponatinib—Mental disorder—Prednisone—atopic dermatitis	0.000118	0.000538	CcSEcCtD
Ponatinib—Skin disorder—Methylprednisolone—atopic dermatitis	0.000117	0.000535	CcSEcCtD
Ponatinib—Erythema—Prednisone—atopic dermatitis	0.000117	0.000535	CcSEcCtD
Ponatinib—Malnutrition—Prednisone—atopic dermatitis	0.000117	0.000535	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000117	0.000534	CcSEcCtD
Ponatinib—Hyperhidrosis—Triamcinolone—atopic dermatitis	0.000117	0.000534	CcSEcCtD
Ponatinib—Hyperhidrosis—Methylprednisolone—atopic dermatitis	0.000117	0.000533	CcSEcCtD
Ponatinib—Insomnia—Hydrocortisone—atopic dermatitis	0.000116	0.00053	CcSEcCtD
Ponatinib—Hypertension—Dexamethasone—atopic dermatitis	0.000116	0.00053	CcSEcCtD
Ponatinib—Hypertension—Betamethasone—atopic dermatitis	0.000116	0.00053	CcSEcCtD
Ponatinib—Paraesthesia—Hydrocortisone—atopic dermatitis	0.000115	0.000527	CcSEcCtD
Ponatinib—Myalgia—Betamethasone—atopic dermatitis	0.000114	0.000523	CcSEcCtD
Ponatinib—Myalgia—Dexamethasone—atopic dermatitis	0.000114	0.000523	CcSEcCtD
Ponatinib—Dyspepsia—Hydrocortisone—atopic dermatitis	0.000113	0.000516	CcSEcCtD
Ponatinib—Pain—Prednisolone—atopic dermatitis	0.000112	0.000513	CcSEcCtD
Ponatinib—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000112	0.00051	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000111	0.000506	CcSEcCtD
Ponatinib—Fatigue—Hydrocortisone—atopic dermatitis	0.000111	0.000506	CcSEcCtD
Ponatinib—Vision blurred—Prednisone—atopic dermatitis	0.00011	0.000504	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	0.00011	0.000503	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	0.00011	0.000502	CcSEcCtD
Ponatinib—Pain—Hydrocortisone—atopic dermatitis	0.00011	0.000501	CcSEcCtD
Ponatinib—Oedema—Dexamethasone—atopic dermatitis	0.00011	0.000501	CcSEcCtD
Ponatinib—Oedema—Betamethasone—atopic dermatitis	0.00011	0.000501	CcSEcCtD
Ponatinib—Insomnia—Triamcinolone—atopic dermatitis	0.000109	0.000499	CcSEcCtD
Ponatinib—Insomnia—Methylprednisolone—atopic dermatitis	0.000109	0.000498	CcSEcCtD
Ponatinib—Infection—Dexamethasone—atopic dermatitis	0.000109	0.000498	CcSEcCtD
Ponatinib—Infection—Betamethasone—atopic dermatitis	0.000109	0.000498	CcSEcCtD
Ponatinib—Paraesthesia—Triamcinolone—atopic dermatitis	0.000109	0.000496	CcSEcCtD
Ponatinib—Paraesthesia—Methylprednisolone—atopic dermatitis	0.000108	0.000495	CcSEcCtD
Ponatinib—Anaemia—Prednisone—atopic dermatitis	0.000108	0.000494	CcSEcCtD
Ponatinib—Dyspnoea—Triamcinolone—atopic dermatitis	0.000108	0.000492	CcSEcCtD
Ponatinib—Nervous system disorder—Betamethasone—atopic dermatitis	0.000108	0.000491	CcSEcCtD
Ponatinib—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000108	0.000491	CcSEcCtD
Ponatinib—Thrombocytopenia—Dexamethasone—atopic dermatitis	0.000107	0.000491	CcSEcCtD
Ponatinib—Thrombocytopenia—Betamethasone—atopic dermatitis	0.000107	0.000491	CcSEcCtD
Ponatinib—Dyspepsia—Triamcinolone—atopic dermatitis	0.000106	0.000486	CcSEcCtD
Ponatinib—Dyspepsia—Methylprednisolone—atopic dermatitis	0.000106	0.000485	CcSEcCtD
Ponatinib—Hyperhidrosis—Dexamethasone—atopic dermatitis	0.000106	0.000484	CcSEcCtD
Ponatinib—Hyperhidrosis—Betamethasone—atopic dermatitis	0.000106	0.000484	CcSEcCtD
Ponatinib—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	0.000105	0.000479	CcSEcCtD
Ponatinib—Fatigue—Triamcinolone—atopic dermatitis	0.000104	0.000476	CcSEcCtD
Ponatinib—Fatigue—Methylprednisolone—atopic dermatitis	0.000104	0.000475	CcSEcCtD
Ponatinib—Pain—Triamcinolone—atopic dermatitis	0.000103	0.000472	CcSEcCtD
Ponatinib—Abdominal pain—Hydrocortisone—atopic dermatitis	0.000102	0.000464	CcSEcCtD
Ponatinib—Body temperature increased—Hydrocortisone—atopic dermatitis	0.000102	0.000464	CcSEcCtD
Ponatinib—Hypertension—Prednisone—atopic dermatitis	0.000101	0.000462	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	0.0001	0.000456	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	0.0001	0.000456	CcSEcCtD
Ponatinib—Myalgia—Prednisone—atopic dermatitis	9.97e-05	0.000455	CcSEcCtD
Ponatinib—Arthralgia—Prednisone—atopic dermatitis	9.97e-05	0.000455	CcSEcCtD
Ponatinib—Insomnia—Dexamethasone—atopic dermatitis	9.92e-05	0.000453	CcSEcCtD
Ponatinib—Insomnia—Betamethasone—atopic dermatitis	9.92e-05	0.000453	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	9.9e-05	0.000452	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	9.87e-05	0.00045	CcSEcCtD
Ponatinib—Paraesthesia—Dexamethasone—atopic dermatitis	9.85e-05	0.00045	CcSEcCtD
Ponatinib—Paraesthesia—Betamethasone—atopic dermatitis	9.85e-05	0.00045	CcSEcCtD
Ponatinib—Dyspepsia—Betamethasone—atopic dermatitis	9.66e-05	0.000441	CcSEcCtD
Ponatinib—Dyspepsia—Dexamethasone—atopic dermatitis	9.66e-05	0.000441	CcSEcCtD
Ponatinib—Body temperature increased—Triamcinolone—atopic dermatitis	9.56e-05	0.000436	CcSEcCtD
Ponatinib—Oedema—Prednisone—atopic dermatitis	9.55e-05	0.000436	CcSEcCtD
Ponatinib—Abdominal pain—Methylprednisolone—atopic dermatitis	9.54e-05	0.000436	CcSEcCtD
Ponatinib—Decreased appetite—Betamethasone—atopic dermatitis	9.54e-05	0.000436	CcSEcCtD
Ponatinib—Decreased appetite—Dexamethasone—atopic dermatitis	9.54e-05	0.000436	CcSEcCtD
Ponatinib—Infection—Prednisone—atopic dermatitis	9.49e-05	0.000433	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	9.47e-05	0.000433	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	9.47e-05	0.000433	CcSEcCtD
Ponatinib—Fatigue—Dexamethasone—atopic dermatitis	9.46e-05	0.000432	CcSEcCtD
Ponatinib—Fatigue—Betamethasone—atopic dermatitis	9.46e-05	0.000432	CcSEcCtD
Ponatinib—Pain—Betamethasone—atopic dermatitis	9.38e-05	0.000428	CcSEcCtD
Ponatinib—Pain—Dexamethasone—atopic dermatitis	9.38e-05	0.000428	CcSEcCtD
Ponatinib—Nervous system disorder—Prednisone—atopic dermatitis	9.37e-05	0.000428	CcSEcCtD
Ponatinib—Skin disorder—Prednisone—atopic dermatitis	9.28e-05	0.000424	CcSEcCtD
Ponatinib—Hyperhidrosis—Prednisone—atopic dermatitis	9.24e-05	0.000422	CcSEcCtD
Ponatinib—Asthenia—Hydrocortisone—atopic dermatitis	9.21e-05	0.000421	CcSEcCtD
Ponatinib—Pruritus—Hydrocortisone—atopic dermatitis	9.08e-05	0.000415	CcSEcCtD
Ponatinib—Gastrointestinal pain—Dexamethasone—atopic dermatitis	8.97e-05	0.00041	CcSEcCtD
Ponatinib—Gastrointestinal pain—Betamethasone—atopic dermatitis	8.97e-05	0.00041	CcSEcCtD
Ponatinib—Diarrhoea—Hydrocortisone—atopic dermatitis	8.79e-05	0.000401	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Prednisone—atopic dermatitis	8.7e-05	0.000397	CcSEcCtD
Ponatinib—Dizziness—Prednisolone—atopic dermatitis	8.69e-05	0.000397	CcSEcCtD
Ponatinib—Asthenia—Triamcinolone—atopic dermatitis	8.67e-05	0.000396	CcSEcCtD
Ponatinib—Body temperature increased—Betamethasone—atopic dermatitis	8.67e-05	0.000396	CcSEcCtD
Ponatinib—Abdominal pain—Dexamethasone—atopic dermatitis	8.67e-05	0.000396	CcSEcCtD
Ponatinib—Abdominal pain—Betamethasone—atopic dermatitis	8.67e-05	0.000396	CcSEcCtD
Ponatinib—Body temperature increased—Dexamethasone—atopic dermatitis	8.67e-05	0.000396	CcSEcCtD
Ponatinib—Asthenia—Methylprednisolone—atopic dermatitis	8.66e-05	0.000395	CcSEcCtD
Ponatinib—Insomnia—Prednisone—atopic dermatitis	8.64e-05	0.000395	CcSEcCtD
Ponatinib—Paraesthesia—Prednisone—atopic dermatitis	8.58e-05	0.000392	CcSEcCtD
Ponatinib—Pruritus—Triamcinolone—atopic dermatitis	8.55e-05	0.000391	CcSEcCtD
Ponatinib—Pruritus—Methylprednisolone—atopic dermatitis	8.54e-05	0.00039	CcSEcCtD
Ponatinib—Dizziness—Hydrocortisone—atopic dermatitis	8.49e-05	0.000388	CcSEcCtD
Ponatinib—Dyspepsia—Prednisone—atopic dermatitis	8.41e-05	0.000384	CcSEcCtD
Ponatinib—Decreased appetite—Prednisone—atopic dermatitis	8.31e-05	0.000379	CcSEcCtD
Ponatinib—Rash—Prednisolone—atopic dermatitis	8.29e-05	0.000379	CcSEcCtD
Ponatinib—Dermatitis—Prednisolone—atopic dermatitis	8.28e-05	0.000378	CcSEcCtD
Ponatinib—Diarrhoea—Methylprednisolone—atopic dermatitis	8.25e-05	0.000377	CcSEcCtD
Ponatinib—Fatigue—Prednisone—atopic dermatitis	8.24e-05	0.000376	CcSEcCtD
Ponatinib—Headache—Prednisolone—atopic dermatitis	8.24e-05	0.000376	CcSEcCtD
Ponatinib—Constipation—Prednisone—atopic dermatitis	8.17e-05	0.000373	CcSEcCtD
Ponatinib—Vomiting—Hydrocortisone—atopic dermatitis	8.16e-05	0.000373	CcSEcCtD
Ponatinib—Rash—Hydrocortisone—atopic dermatitis	8.1e-05	0.00037	CcSEcCtD
Ponatinib—Dermatitis—Hydrocortisone—atopic dermatitis	8.09e-05	0.000369	CcSEcCtD
Ponatinib—Headache—Hydrocortisone—atopic dermatitis	8.04e-05	0.000367	CcSEcCtD
Ponatinib—Dizziness—Triamcinolone—atopic dermatitis	8e-05	0.000365	CcSEcCtD
Ponatinib—Dizziness—Methylprednisolone—atopic dermatitis	7.98e-05	0.000364	CcSEcCtD
Ponatinib—Asthenia—Dexamethasone—atopic dermatitis	7.87e-05	0.000359	CcSEcCtD
Ponatinib—Asthenia—Betamethasone—atopic dermatitis	7.87e-05	0.000359	CcSEcCtD
Ponatinib—Gastrointestinal pain—Prednisone—atopic dermatitis	7.81e-05	0.000357	CcSEcCtD
Ponatinib—Nausea—Prednisolone—atopic dermatitis	7.81e-05	0.000357	CcSEcCtD
Ponatinib—Pruritus—Betamethasone—atopic dermatitis	7.76e-05	0.000354	CcSEcCtD
Ponatinib—Pruritus—Dexamethasone—atopic dermatitis	7.76e-05	0.000354	CcSEcCtD
Ponatinib—Vomiting—Triamcinolone—atopic dermatitis	7.69e-05	0.000351	CcSEcCtD
Ponatinib—Vomiting—Methylprednisolone—atopic dermatitis	7.67e-05	0.00035	CcSEcCtD
Ponatinib—Nausea—Hydrocortisone—atopic dermatitis	7.63e-05	0.000348	CcSEcCtD
Ponatinib—Rash—Triamcinolone—atopic dermatitis	7.62e-05	0.000348	CcSEcCtD
Ponatinib—Dermatitis—Triamcinolone—atopic dermatitis	7.62e-05	0.000348	CcSEcCtD
Ponatinib—Rash—Methylprednisolone—atopic dermatitis	7.61e-05	0.000347	CcSEcCtD
Ponatinib—Dermatitis—Methylprednisolone—atopic dermatitis	7.6e-05	0.000347	CcSEcCtD
Ponatinib—Headache—Triamcinolone—atopic dermatitis	7.57e-05	0.000346	CcSEcCtD
Ponatinib—Headache—Methylprednisolone—atopic dermatitis	7.56e-05	0.000345	CcSEcCtD
Ponatinib—Abdominal pain—Prednisone—atopic dermatitis	7.55e-05	0.000345	CcSEcCtD
Ponatinib—Body temperature increased—Prednisone—atopic dermatitis	7.55e-05	0.000345	CcSEcCtD
Ponatinib—Diarrhoea—Dexamethasone—atopic dermatitis	7.51e-05	0.000343	CcSEcCtD
Ponatinib—Diarrhoea—Betamethasone—atopic dermatitis	7.51e-05	0.000343	CcSEcCtD
Ponatinib—Dizziness—Dexamethasone—atopic dermatitis	7.25e-05	0.000331	CcSEcCtD
Ponatinib—Dizziness—Betamethasone—atopic dermatitis	7.25e-05	0.000331	CcSEcCtD
Ponatinib—Nausea—Triamcinolone—atopic dermatitis	7.18e-05	0.000328	CcSEcCtD
Ponatinib—Nausea—Methylprednisolone—atopic dermatitis	7.17e-05	0.000327	CcSEcCtD
Ponatinib—Vomiting—Dexamethasone—atopic dermatitis	6.98e-05	0.000319	CcSEcCtD
Ponatinib—Vomiting—Betamethasone—atopic dermatitis	6.98e-05	0.000319	CcSEcCtD
Ponatinib—Rash—Betamethasone—atopic dermatitis	6.92e-05	0.000316	CcSEcCtD
Ponatinib—Rash—Dexamethasone—atopic dermatitis	6.92e-05	0.000316	CcSEcCtD
Ponatinib—Dermatitis—Dexamethasone—atopic dermatitis	6.91e-05	0.000316	CcSEcCtD
Ponatinib—Dermatitis—Betamethasone—atopic dermatitis	6.91e-05	0.000316	CcSEcCtD
Ponatinib—Headache—Dexamethasone—atopic dermatitis	6.87e-05	0.000314	CcSEcCtD
Ponatinib—Headache—Betamethasone—atopic dermatitis	6.87e-05	0.000314	CcSEcCtD
Ponatinib—Asthenia—Prednisone—atopic dermatitis	6.85e-05	0.000313	CcSEcCtD
Ponatinib—Pruritus—Prednisone—atopic dermatitis	6.76e-05	0.000309	CcSEcCtD
Ponatinib—Diarrhoea—Prednisone—atopic dermatitis	6.54e-05	0.000299	CcSEcCtD
Ponatinib—Nausea—Dexamethasone—atopic dermatitis	6.52e-05	0.000298	CcSEcCtD
Ponatinib—Nausea—Betamethasone—atopic dermatitis	6.52e-05	0.000298	CcSEcCtD
Ponatinib—Dizziness—Prednisone—atopic dermatitis	6.32e-05	0.000289	CcSEcCtD
Ponatinib—Vomiting—Prednisone—atopic dermatitis	6.07e-05	0.000277	CcSEcCtD
Ponatinib—Rash—Prednisone—atopic dermatitis	6.02e-05	0.000275	CcSEcCtD
Ponatinib—Dermatitis—Prednisone—atopic dermatitis	6.02e-05	0.000275	CcSEcCtD
Ponatinib—Headache—Prednisone—atopic dermatitis	5.99e-05	0.000273	CcSEcCtD
Ponatinib—Nausea—Prednisone—atopic dermatitis	5.68e-05	0.000259	CcSEcCtD
Ponatinib—LYN—Signaling Pathways—TAC1—atopic dermatitis	2.19e-05	0.000139	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NPS—atopic dermatitis	2.19e-05	0.000139	CbGpPWpGaD
Ponatinib—FGFR1—Axon guidance—IL6—atopic dermatitis	2.18e-05	0.000139	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL11—atopic dermatitis	2.18e-05	0.000139	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CMA1—atopic dermatitis	2.18e-05	0.000139	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CCR5—atopic dermatitis	2.18e-05	0.000139	CbGpPWpGaD
Ponatinib—SRC—Immune System—TLR2—atopic dermatitis	2.17e-05	0.000138	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CCR5—atopic dermatitis	2.17e-05	0.000138	CbGpPWpGaD
Ponatinib—LYN—Cytokine Signaling in Immune system—IL6—atopic dermatitis	2.16e-05	0.000137	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—MAPK8—atopic dermatitis	2.16e-05	0.000137	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—CD4—atopic dermatitis	2.15e-05	0.000137	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—MAPK8—atopic dermatitis	2.15e-05	0.000137	CbGpPWpGaD
Ponatinib—FGFR3—Innate Immune System—IL6—atopic dermatitis	2.15e-05	0.000137	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—NFKBIA—atopic dermatitis	2.15e-05	0.000137	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCR3—atopic dermatitis	2.14e-05	0.000136	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL1B—atopic dermatitis	2.14e-05	0.000136	CbGpPWpGaD
Ponatinib—FGFR3—Disease—CD4—atopic dermatitis	2.14e-05	0.000136	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NGF—atopic dermatitis	2.13e-05	0.000136	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL2—atopic dermatitis	2.13e-05	0.000135	CbGpPWpGaD
Ponatinib—KDR—Developmental Biology—IL6—atopic dermatitis	2.12e-05	0.000135	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCL10—atopic dermatitis	2.11e-05	0.000134	CbGpPWpGaD
Ponatinib—KIT—Immune System—NFKBIA—atopic dermatitis	2.11e-05	0.000134	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—NFKBIA—atopic dermatitis	2.11e-05	0.000134	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CCR5—atopic dermatitis	2.07e-05	0.000132	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL10—atopic dermatitis	2.07e-05	0.000132	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT6—atopic dermatitis	2.05e-05	0.000131	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD79A—atopic dermatitis	2.04e-05	0.00013	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GLB1—atopic dermatitis	2.04e-05	0.00013	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL5—atopic dermatitis	2.03e-05	0.000129	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NFKBIA—atopic dermatitis	2.02e-05	0.000128	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCR3—atopic dermatitis	2.01e-05	0.000128	CbGpPWpGaD
Ponatinib—SRC—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	2e-05	0.000127	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—NFKBIA—atopic dermatitis	2e-05	0.000127	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—NFKBIA—atopic dermatitis	2e-05	0.000127	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—CASP8—atopic dermatitis	1.98e-05	0.000126	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	1.97e-05	0.000125	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL10—atopic dermatitis	1.97e-05	0.000125	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL10—atopic dermatitis	1.96e-05	0.000125	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—MAPK8—atopic dermatitis	1.96e-05	0.000125	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ADSL—atopic dermatitis	1.95e-05	0.000124	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—CXCL8—atopic dermatitis	1.95e-05	0.000124	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CASP8—atopic dermatitis	1.94e-05	0.000123	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—TNF—atopic dermatitis	1.93e-05	0.000123	CbGpPWpGaD
Ponatinib—LYN—Axon guidance—IL6—atopic dermatitis	1.92e-05	0.000122	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GLB1—atopic dermatitis	1.92e-05	0.000122	CbGpPWpGaD
Ponatinib—ABL1—Axon guidance—IL6—atopic dermatitis	1.91e-05	0.000122	CbGpPWpGaD
Ponatinib—KIT—Immune System—CASP8—atopic dermatitis	1.9e-05	0.000121	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—MAPK8—atopic dermatitis	1.9e-05	0.000121	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL18—atopic dermatitis	1.89e-05	0.00012	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—MAPK8—atopic dermatitis	1.89e-05	0.00012	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—IL2—atopic dermatitis	1.88e-05	0.000119	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD8A—atopic dermatitis	1.86e-05	0.000118	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL2—atopic dermatitis	1.86e-05	0.000118	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PPARA—atopic dermatitis	1.85e-05	0.000118	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ADSL—atopic dermatitis	1.84e-05	0.000117	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—CD4—atopic dermatitis	1.84e-05	0.000117	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCL5—atopic dermatitis	1.82e-05	0.000116	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CASP8—atopic dermatitis	1.81e-05	0.000115	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CASP8—atopic dermatitis	1.8e-05	0.000115	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NPS—atopic dermatitis	1.79e-05	0.000114	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TAC1—atopic dermatitis	1.79e-05	0.000114	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCL5—atopic dermatitis	1.79e-05	0.000114	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCR3—atopic dermatitis	1.78e-05	0.000113	CbGpPWpGaD
Ponatinib—LCK—Cytokine Signaling in Immune system—IL6—atopic dermatitis	1.77e-05	0.000113	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—CD4—atopic dermatitis	1.76e-05	0.000112	CbGpPWpGaD
Ponatinib—LYN—Immune System—NFKBIA—atopic dermatitis	1.76e-05	0.000112	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NFKBIA—atopic dermatitis	1.76e-05	0.000112	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCR3—atopic dermatitis	1.76e-05	0.000112	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NFKBIA—atopic dermatitis	1.75e-05	0.000112	CbGpPWpGaD
Ponatinib—LCK—Signaling by NGF—IL6—atopic dermatitis	1.74e-05	0.000111	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL10—atopic dermatitis	1.73e-05	0.00011	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—MAPK8—atopic dermatitis	1.71e-05	0.000109	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.7e-05	0.000108	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—TNF—atopic dermatitis	1.7e-05	0.000108	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCL5—atopic dermatitis	1.69e-05	0.000108	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—TNF—atopic dermatitis	1.69e-05	0.000108	CbGpPWpGaD
Ponatinib—FGFR4—Immune System—IL6—atopic dermatitis	1.69e-05	0.000108	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCL5—atopic dermatitis	1.69e-05	0.000108	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NGF—atopic dermatitis	1.68e-05	0.000107	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL18—atopic dermatitis	1.67e-05	0.000106	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL5—atopic dermatitis	1.67e-05	0.000106	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—IL2—atopic dermatitis	1.66e-05	0.000106	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NGF—atopic dermatitis	1.65e-05	0.000105	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD8A—atopic dermatitis	1.65e-05	0.000105	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IFNG—atopic dermatitis	1.65e-05	0.000105	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCR5—atopic dermatitis	1.64e-05	0.000104	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—CD4—atopic dermatitis	1.63e-05	0.000103	CbGpPWpGaD
Ponatinib—KIT—Immune System—IFNG—atopic dermatitis	1.62e-05	0.000103	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCR5—atopic dermatitis	1.61e-05	0.000102	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—CD4—atopic dermatitis	1.59e-05	0.000101	CbGpPWpGaD
Ponatinib—LYN—Immune System—CASP8—atopic dermatitis	1.59e-05	0.000101	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NPS—atopic dermatitis	1.59e-05	0.000101	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TAC1—atopic dermatitis	1.59e-05	0.000101	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CASP8—atopic dermatitis	1.58e-05	0.000101	CbGpPWpGaD
Ponatinib—LCK—Disease—CCR5—atopic dermatitis	1.57e-05	0.0001	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NGF—atopic dermatitis	1.57e-05	9.98e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NGF—atopic dermatitis	1.57e-05	9.96e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—CD4—atopic dermatitis	1.56e-05	9.94e-05	CbGpPWpGaD
Ponatinib—FGFR4—Disease—IL6—atopic dermatitis	1.56e-05	9.93e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—CD4—atopic dermatitis	1.56e-05	9.93e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	1.56e-05	9.93e-05	CbGpPWpGaD
Ponatinib—FGFR1—Developmental Biology—IL6—atopic dermatitis	1.56e-05	9.92e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—MAPK8—atopic dermatitis	1.55e-05	9.89e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCR3—atopic dermatitis	1.55e-05	9.89e-05	CbGpPWpGaD
Ponatinib—BCR—Signaling Pathways—IL6—atopic dermatitis	1.55e-05	9.87e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling by NGF—IL6—atopic dermatitis	1.54e-05	9.8e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IFNG—atopic dermatitis	1.54e-05	9.77e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IFNG—atopic dermatitis	1.53e-05	9.74e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCR5—atopic dermatitis	1.53e-05	9.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCR5—atopic dermatitis	1.52e-05	9.69e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCL5—atopic dermatitis	1.49e-05	9.48e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—CD4—atopic dermatitis	1.48e-05	9.43e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—CD4—atopic dermatitis	1.48e-05	9.41e-05	CbGpPWpGaD
Ponatinib—FGFR2—Innate Immune System—IL6—atopic dermatitis	1.48e-05	9.4e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL5—atopic dermatitis	1.47e-05	9.38e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL1B—atopic dermatitis	1.47e-05	9.35e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—CD4—atopic dermatitis	1.47e-05	9.34e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL2—atopic dermatitis	1.46e-05	9.31e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—IL6—atopic dermatitis	1.45e-05	9.23e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NFKBIA—atopic dermatitis	1.44e-05	9.18e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL1B—atopic dermatitis	1.44e-05	9.18e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—CD4—atopic dermatitis	1.44e-05	9.18e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CXCL8—atopic dermatitis	1.44e-05	9.16e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL2—atopic dermatitis	1.44e-05	9.15e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL10—atopic dermatitis	1.42e-05	9.03e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	1.41e-05	8.98e-05	CbGpPWpGaD
Ponatinib—SRC—Axon guidance—IL6—atopic dermatitis	1.39e-05	8.87e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CCR5—atopic dermatitis	1.39e-05	8.85e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NFKBIA—atopic dermatitis	1.39e-05	8.83e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NGF—atopic dermatitis	1.38e-05	8.78e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—IL6—atopic dermatitis	1.38e-05	8.76e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—MAPK8—atopic dermatitis	1.38e-05	8.76e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL2—atopic dermatitis	1.38e-05	8.75e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—IL6—atopic dermatitis	1.37e-05	8.74e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—IL6—atopic dermatitis	1.37e-05	8.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL1B—atopic dermatitis	1.37e-05	8.71e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CD4—atopic dermatitis	1.37e-05	8.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL1B—atopic dermatitis	1.37e-05	8.69e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CD4—atopic dermatitis	1.37e-05	8.69e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—IL6—atopic dermatitis	1.37e-05	8.69e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL2—atopic dermatitis	1.36e-05	8.68e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NFKBIA—atopic dermatitis	1.36e-05	8.68e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL2—atopic dermatitis	1.36e-05	8.66e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IFNG—atopic dermatitis	1.35e-05	8.59e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—MAPK8—atopic dermatitis	1.35e-05	8.57e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IFNG—atopic dermatitis	1.34e-05	8.55e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCR5—atopic dermatitis	1.34e-05	8.54e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—MAPK8—atopic dermatitis	1.32e-05	8.42e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—CD4—atopic dermatitis	1.3e-05	8.3e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CASP8—atopic dermatitis	1.3e-05	8.28e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CD4—atopic dermatitis	1.3e-05	8.26e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NFKBIA—atopic dermatitis	1.29e-05	8.23e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NFKBIA—atopic dermatitis	1.29e-05	8.21e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NFKBIA—atopic dermatitis	1.28e-05	8.13e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MAPK8—atopic dermatitis	1.27e-05	8.06e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL10—atopic dermatitis	1.26e-05	8e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—MAPK8—atopic dermatitis	1.26e-05	7.99e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GLB1—atopic dermatitis	1.26e-05	7.98e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CXCL8—atopic dermatitis	1.25e-05	7.98e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—MAPK8—atopic dermatitis	1.25e-05	7.97e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—IL6—atopic dermatitis	1.25e-05	7.96e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—TNF—atopic dermatitis	1.23e-05	7.85e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PPARA—atopic dermatitis	1.22e-05	7.78e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL5—atopic dermatitis	1.22e-05	7.77e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—IL6—atopic dermatitis	1.21e-05	7.71e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—IL6—atopic dermatitis	1.21e-05	7.67e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL1B—atopic dermatitis	1.2e-05	7.66e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ADSL—atopic dermatitis	1.2e-05	7.66e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL2—atopic dermatitis	1.2e-05	7.64e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL1B—atopic dermatitis	1.2e-05	7.63e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL2—atopic dermatitis	1.2e-05	7.63e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL2—atopic dermatitis	1.19e-05	7.6e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—IL6—atopic dermatitis	1.16e-05	7.35e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CASP8—atopic dermatitis	1.15e-05	7.33e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NFKBIA—atopic dermatitis	1.14e-05	7.24e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NGF—atopic dermatitis	1.13e-05	7.2e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IFNG—atopic dermatitis	1.11e-05	7.04e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MAPK8—atopic dermatitis	1.1e-05	7.03e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MAPK8—atopic dermatitis	1.1e-05	7.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCR5—atopic dermatitis	1.1e-05	7e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MAPK8—atopic dermatitis	1.1e-05	7e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—IL6—atopic dermatitis	1.09e-05	6.96e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL5—atopic dermatitis	1.08e-05	6.88e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CD4—atopic dermatitis	1.07e-05	6.8e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NGF—atopic dermatitis	1e-05	6.37e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—IL6—atopic dermatitis	9.95e-06	6.33e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—IL6—atopic dermatitis	9.93e-06	6.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CXCL8—atopic dermatitis	9.9e-06	6.3e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1B—atopic dermatitis	9.88e-06	6.28e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CD4—atopic dermatitis	9.87e-06	6.28e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—atopic dermatitis	9.84e-06	6.26e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IFNG—atopic dermatitis	9.8e-06	6.24e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCR5—atopic dermatitis	9.75e-06	6.2e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CXCL8—atopic dermatitis	9.73e-06	6.19e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CD4—atopic dermatitis	9.47e-06	6.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—atopic dermatitis	9.46e-06	6.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NFKBIA—atopic dermatitis	9.33e-06	5.94e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—atopic dermatitis	9.3e-06	5.91e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CXCL8—atopic dermatitis	9.23e-06	5.87e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CXCL8—atopic dermatitis	9.21e-06	5.86e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK8—atopic dermatitis	9.06e-06	5.76e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—atopic dermatitis	8.82e-06	5.61e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—atopic dermatitis	8.8e-06	5.6e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—IL6—atopic dermatitis	8.79e-06	5.59e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARA—atopic dermatitis	8.76e-06	5.57e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—atopic dermatitis	8.74e-06	5.56e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CD4—atopic dermatitis	8.74e-06	5.56e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK8—atopic dermatitis	8.71e-06	5.54e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—atopic dermatitis	8.71e-06	5.54e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—IL6—atopic dermatitis	8.6e-06	5.47e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK8—atopic dermatitis	8.56e-06	5.44e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—IL6—atopic dermatitis	8.45e-06	5.38e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKBIA—atopic dermatitis	8.26e-06	5.26e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—atopic dermatitis	8.12e-06	5.17e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK8—atopic dermatitis	8.12e-06	5.17e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK8—atopic dermatitis	8.1e-06	5.15e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—IL6—atopic dermatitis	8.09e-06	5.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—IL6—atopic dermatitis	8.02e-06	5.1e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK8—atopic dermatitis	8.02e-06	5.1e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—IL6—atopic dermatitis	8e-06	5.09e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—IL6—atopic dermatitis	7.94e-06	5.05e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—IL6—atopic dermatitis	7.8e-06	4.96e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—atopic dermatitis	7.76e-06	4.94e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARA—atopic dermatitis	7.59e-06	4.83e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—IL6—atopic dermatitis	7.4e-06	4.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—IL6—atopic dermatitis	7.39e-06	4.7e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK8—atopic dermatitis	7.14e-06	4.54e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—IL6—atopic dermatitis	7.06e-06	4.49e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—IL6—atopic dermatitis	7.05e-06	4.48e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—IL6—atopic dermatitis	7.02e-06	4.47e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—atopic dermatitis	6.66e-06	4.23e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARA—atopic dermatitis	6.61e-06	4.21e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—atopic dermatitis	6.36e-06	4.05e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARA—atopic dermatitis	6.23e-06	3.96e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—atopic dermatitis	5.89e-06	3.75e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK8—atopic dermatitis	5.86e-06	3.72e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL6—atopic dermatitis	5.78e-06	3.68e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—atopic dermatitis	5.63e-06	3.58e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL6—atopic dermatitis	5.56e-06	3.54e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL6—atopic dermatitis	5.46e-06	3.48e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—IL6—atopic dermatitis	5.34e-06	3.4e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL6—atopic dermatitis	5.19e-06	3.3e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK8—atopic dermatitis	5.18e-06	3.3e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL6—atopic dermatitis	5.17e-06	3.29e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL6—atopic dermatitis	5.12e-06	3.26e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—IL6—atopic dermatitis	4.73e-06	3.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6—atopic dermatitis	4.56e-06	2.9e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARA—atopic dermatitis	4.07e-06	2.59e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6—atopic dermatitis	3.74e-06	2.38e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6—atopic dermatitis	3.31e-06	2.11e-05	CbGpPWpGaD
